Sihang Cheng1,2, Xiang Yu2, Siyun Liu3, Zhengyu Jin1, Huadan Xue1, Zhiwei Wang1, Ping Xie2. 1. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. 2. Department of Radiology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu, People's Republic of China. 3. Pharmaceutical Diagnostics, GE Healthcare, Beijing, People's Republic of China.
Abstract
OBJECTIVE: To develop and validate a prognostic nomogram in eastern patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) receiving trans-arterial chemoembolization with drug-eluting beads (DEB-TACE). METHODS: This retrospective study included 200 patients with training cohort (n = 118) from institution 1 and test cohort (n = 82) from institution 2. All these patients received first-line DEB-TACE between October 2016 and October 2018. Multivariate Cox proportional hazard regression analysis was performed on the training cohort to reveal the independent prognostic factors, and then prognostic nomograms were developed. In order to evaluate the performance of the nomogram comprehensively in both the training and test cohorts, C-index, Kaplan-Meier curve with Log rank test, receiver operating characteristic curve (ROC), calibration plot, and decision curve analysis (DCA) were performed. RESULTS: Tumor number, serum γ-glutamyl transferase (GGT) level, and level of PVTT were independent risk factors of prognosis. A nomogram was constructed to predict 6-, 12- and 18-month overall survival (OS) based on these identified prognostic factors. C-indexes of the nomogram were 0.88 (95% confidence interval [CI], 0.79-0.97) in the training cohort and 0.87 (95% CI, 0.75-0.99) in the test cohort. The Kaplan-Meier curve analysis showed that the nomogram was able to separate patients into low- and high-risk subgroups. ROC curves for the nomogram at 6-, 12- and 18-month showed satisfied discrimination, with an AUC of 0.765, 0.803 and 0.809 in the training cohort, respectively, and 0.772, 0.724 and 0.746 in the test cohort, respectively. The calibration curve demonstrated good agreement between predicted and actual survival rates in the training and test cohorts. The decision curve showed good performance of the nomogram in terms of clinical application. CONCLUSION: We developed and validated a nomogram that was accurate and clinically useful in eastern patients with HBV-associated HCC with PVTT who underwent DEB-TACE.
OBJECTIVE: To develop and validate a prognostic nomogram in eastern patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) receiving trans-arterial chemoembolization with drug-eluting beads (DEB-TACE). METHODS: This retrospective study included 200 patients with training cohort (n = 118) from institution 1 and test cohort (n = 82) from institution 2. All these patients received first-line DEB-TACE between October 2016 and October 2018. Multivariate Cox proportional hazard regression analysis was performed on the training cohort to reveal the independent prognostic factors, and then prognostic nomograms were developed. In order to evaluate the performance of the nomogram comprehensively in both the training and test cohorts, C-index, Kaplan-Meier curve with Log rank test, receiver operating characteristic curve (ROC), calibration plot, and decision curve analysis (DCA) were performed. RESULTS: Tumor number, serum γ-glutamyl transferase (GGT) level, and level of PVTT were independent risk factors of prognosis. A nomogram was constructed to predict 6-, 12- and 18-month overall survival (OS) based on these identified prognostic factors. C-indexes of the nomogram were 0.88 (95% confidence interval [CI], 0.79-0.97) in the training cohort and 0.87 (95% CI, 0.75-0.99) in the test cohort. The Kaplan-Meier curve analysis showed that the nomogram was able to separate patients into low- and high-risk subgroups. ROC curves for the nomogram at 6-, 12- and 18-month showed satisfied discrimination, with an AUC of 0.765, 0.803 and 0.809 in the training cohort, respectively, and 0.772, 0.724 and 0.746 in the test cohort, respectively. The calibration curve demonstrated good agreement between predicted and actual survival rates in the training and test cohorts. The decision curve showed good performance of the nomogram in terms of clinical application. CONCLUSION: We developed and validated a nomogram that was accurate and clinically useful in eastern patients with HBV-associated HCC with PVTT who underwent DEB-TACE.
Authors: Boris Gorodetski; Julius Chapiro; Ruediger Schernthaner; Rafael Duran; MingDe Lin; Howard Lee; David Lenis; Elizabeth A Stuart; Bareng Aletta Sanny Nonyane; Vasily Pekurovsky; Anobel Tamrazi; Bernhard Gebauer; Todd Schlachter; Timothy M Pawlik; Jean-Francois Geschwind Journal: Eur Radiol Date: 2016-06-08 Impact factor: 5.315
Authors: Beom Kyung Kim; Ju Hyun Shim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kang Mo Kim; Young-Suk Lim; Kwang-Hyub Han; Han Chu Lee Journal: Liver Int Date: 2015-05-31 Impact factor: 5.828
Authors: Nihal Mostafa; Ahmed Salem; Somaya Z Mansour; Sawsan M El-Sonbaty; Fatma S M Moawed; Eman I Kandil Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec